

Howard L Mcleod

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6704587/publications.pdf>

Version: 2024-02-01

498
papers

30,885
citations

5782

84
h-index

7234

158
g-index

517
all docs

517
docs citations

517
times ranked

33454
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomics and Drug Disposition, Drug Targets, and Side Effects. <i>New England Journal of Medicine</i> , 2003, 348, 538-549.	13.9	1,609
2	Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose. <i>New England Journal of Medicine</i> , 2005, 352, 2285-2293.	13.9	1,348
3	Doxorubicin pathways. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 440-446.	0.7	1,167
4	Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 326-331.	2.3	743
5	Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153.	13.9	552
6	Platinum neurotoxicity pharmacogenetics. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 10-16.	1.9	500
7	UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1290-1295.	3.0	436
8	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2000, 14, 567-572.	3.3	422
9	Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. <i>Pharmacogenomics</i> , 2008, 9, 1543-1546.	0.6	421
10	Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs. <i>Clinical Pharmacokinetics</i> , 2005, 44, 279-304.	1.6	419
11	Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1564-1571.	0.8	411
12	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 210-216.	2.3	407
13	PI3K/Akt/mTOR pathway as a target for cancer therapy. <i>Anti-Cancer Drugs</i> , 2005, 16, 797-803.	0.7	396
14	A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. <i>Lancet Oncology</i> , 2017, 18, 202-211.	5.1	377
15	MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 217-221.	5.7	373
16	The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 37-42.	5.7	354
17	Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine. <i>Annals of Internal Medicine</i> , 1998, 129, 716.	2.0	334
18	Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. <i>Journal of Clinical Investigation</i> , 1996, 98, 610-615.	3.9	312

#	ARTICLE	IF	CITATIONS
19	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. <i>Thrombosis and Haemostasis</i> , 2004, 91, 87-94.	1.8	308
20	PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 101-121.	4.2	302
21	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	12.8	287
22	The thiopurine S-methyltransferase gene locus " implications for clinical pharmacogenomics. <i>Pharmacogenomics</i> , 2002, 3, 89-98.	0.6	275
23	Pharmacogenomics. <i>Lancet</i> , The, 2019, 394, 521-532.	6.3	261
24	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 112-121.	5.1	249
25	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 770-777.	2.3	244
26	Thiopurine methyltransferase activity in American white subjects and black subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 15-20.	2.3	242
27	CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer. <i>Cancer Research</i> , 2005, 65, 8961-8967.	0.4	241
28	Pharmacogenomics: Challenges and Opportunities. <i>Annals of Internal Medicine</i> , 2006, 145, 749.	2.0	228
29	Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 38-44.	2.3	222
30	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
31	Biomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 673-688.	0.4	215
32	Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4528-4535.	0.8	213
33	ABCG2 Pharmacogenetics. <i>Clinical Cancer Research</i> , 2004, 10, 5889-5894.	3.2	211
34	Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. <i>Clinical Cancer Research</i> , 2002, 8, 2605-11.	3.2	210
35	Disulfiram-mediated inhibition of NF- κ B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. <i>International Journal of Cancer</i> , 2003, 104, 504-511.	2.3	206
36	Cytochrome P450 2C9-CYP2C9. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 277-281.	0.7	205

#	ARTICLE	IF	CITATIONS
37	Validation of Analytic Methods for Biomarkers Used in Drug Development. <i>Clinical Cancer Research</i> , 2008, 14, 5967-5976.	3.2	202
38	Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 282-297.	2.3	201
39	Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741. <i>Journal of Clinical Oncology</i> , 2010, 28, 3227-3233.	0.8	198
40	Genomic Medicine: A Decade of Successes, Challenges, and Opportunities. <i>Science Translational Medicine</i> , 2013, 5, 189sr4.	5.8	197
41	A High-Resolution Map of Segmental DNA Copy Number Variation in the Mouse Genome. <i>PLoS Genetics</i> , 2007, 3, e3.	1.5	196
42	Ethnic Variation in the Thymidylate Synthase Enhancer Region Polymorphism among Caucasian and Asian Populations. <i>Genomics</i> , 1999, 58, 310-312.	1.3	194
43	Contrasting patterns of Y chromosome and mtDNA variation in Africa: evidence for sex-biased demographic processes. <i>European Journal of Human Genetics</i> , 2005, 13, 867-876.	1.4	190
44	Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics. <i>Journal of Clinical Oncology</i> , 2009, 27, 3540-3546.	0.8	189
45	Irinotecan pathway genotype analysis to predict pharmacokinetics. <i>Clinical Cancer Research</i> , 2003, 9, 3246-53.	3.2	189
46	Cancer pharmacogenetics: polymorphisms, pathways and beyond. <i>Nature Reviews Cancer</i> , 2003, 3, 912-920.	12.8	187
47	A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101. <i>Clinical Cancer Research</i> , 2012, 18, 5099-5109.	3.2	183
48	β_2 -Adrenergic Receptor Genotype and Survival Among Patients Receiving β_2 -Blocker Therapy After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1526.	3.8	177
49	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. <i>Thrombosis and Haemostasis</i> , 2005, 93, 700-705.	1.8	176
50	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3232-3239.	0.8	173
51	Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel. <i>Clinical Cancer Research</i> , 2005, 11, 8097-8104.	3.2	170
52	Ethnic differences in thiopurine methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 773-776.	5.7	167
53	Knockdown of RNA Binding Protein Musashi-1 Leads to Tumor Regression In Vivo. <i>Gastroenterology</i> , 2008, 134, 1448-1458.e2.	0.6	163
54	Characterization of the Human Dihydropyrimidine Dehydrogenase Gene. <i>Genomics</i> , 1998, 51, 391-400.	1.3	158

#	ARTICLE	IF	CITATIONS
55	Cytochrome P450 CYP1B1 protein expression: Biochemical Pharmacology, 2001, 62, 207-212.	2.0	153
56	Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 2015, 7, 290ps13.	5.8	146
57	Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11809-11814.	3.3	142
58	Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed. Science, 2013, 339, 1563-1566.	6.0	142
59	Genetic and clinical factors relating to warfarin dosing. Trends in Pharmacological Sciences, 2009, 30, 375-386.	4.0	126
60	Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1366-1377.	6.7	122
61	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	0.7	120
62	A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics and Genomics, 2004, 14, 329-332.	5.7	118
63	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5961-5971.	3.2	118
64	Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. British Journal of Clinical Pharmacology, 1998, 46, 151-156.	1.1	113
65	Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clinical Pharmacology and Therapeutics, 2018, 103, 778-786.	2.3	110
66	Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 572-9.	1.0	110
67	Pharmacogenomic Discovery Using Cell-Based Models. Pharmacological Reviews, 2009, 61, 413-429.	7.1	109
68	Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. British Journal of Haematology, 1999, 105, 696-700.	1.2	108
69	Genetic basis of drug metabolism. American Journal of Health-System Pharmacy, 2002, 59, 2061-2069.	0.5	107
70	Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics, 2004, 84, 661-668.	1.3	105
71	Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenetics and Genomics, 2013, 23, 242-248.	0.7	104
72	Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics and Genomics, 2001, 11, 275-278.	5.7	103

#	ARTICLE	IF	CITATIONS
73	Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research. <i>Cell</i> , 2017, 169, 6-12.	13.5	103
74	Should DPD analysis be required prior to prescribing fluoropyrimidines?. <i>European Journal of Cancer</i> , 2007, 43, 1011-1016.	1.3	102
75	Novel thymidylate synthase enhancer region alleles in African populations. <i>Human Mutation</i> , 2000, 16, 528-528.	1.1	100
76	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. <i>Pharmacogenomics</i> , 2009, 10, 1799-1817.	0.6	100
77	The kinetics and tissue distribution of protein transduction in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 27, 311-319.	1.9	99
78	When will clinical trials finally reflect diversity?. <i>Nature</i> , 2018, 557, 157-159.	13.7	96
79	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 237-242.	0.7	93
80	Strategies for integrating personalized medicine into healthcare practice. <i>Personalized Medicine</i> , 2017, 14, 141-152.	0.8	93
81	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. <i>Clinical Cancer Research</i> , 2012, 18, 577-584.	3.2	91
82	<i>ABCB1</i> (<i>MDR 1</i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 5594-5601.	3.2	90
83	Copy number variants in pharmacogenetic genes. <i>Trends in Molecular Medicine</i> , 2011, 17, 244-251.	3.5	90
84	Thiopurine pathway. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 573-574.	0.7	89
85	Distribution of ITPA P32T alleles in multiple world populations. <i>Journal of Human Genetics</i> , 2004, 49, 579-581.	1.1	88
86	The pharmacogenetics of coumarin therapy. <i>Pharmacogenomics</i> , 2005, 6, 503-513.	0.6	86
87	Thymidylate Synthase Pharmacogenetics in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2001, 1, 175-178.	1.0	83
88	Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. <i>International Journal of Oncology</i> , 2001, 19, 383-6.	1.4	81
89	CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 401-410.	1.1	81
90	Therapeutic Synergy Between Irinotecan and 5-Fluorouracil against Human Tumor Xenografts. <i>Clinical Cancer Research</i> , 2004, 10, 1121-1129.	3.2	77

#	ARTICLE	IF	CITATIONS
91	Implementation of a pharmacogenomics service in a community pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2014, 54, 172-180.	0.7	77
92	Analysis of key cell-cycle checkpoint proteins in colorectal tumours. <i>Journal of Pathology</i> , 2002, 196, 386-393.	2.1	75
93	A novel polymorphism of human gene has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 519-527.	2.3	75
94	CANDID: a flexible method for prioritizing candidate genes for complex human traits. <i>Genetic Epidemiology</i> , 2008, 32, 779-790.	0.6	75
95	Modeling the 5-Fluorouracil Area Under the Curve Versus Dose Relationship to Develop a Pharmacokinetic Dosing Algorithm for Colorectal Cancer Patients Receiving FOLFOX6. <i>Oncologist</i> , 2012, 17, 296-302.	1.9	75
96	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. <i>Pharmacogenetics and Genomics</i> , 1995, 5, 281-286.	5.7	74
97	Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4109-4115.	0.8	74
98	Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. <i>Oncologist</i> , 2017, 22, 144-151.	1.9	74
99	Effect of grapefruit juice intake on etoposide bioavailability. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 491-494.	0.8	73
100	Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes. <i>Clinical Cancer Research</i> , 2008, 14, 1788-1796.	3.2	72
101	Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. <i>International Journal of Cancer</i> , 1994, 59, 607-611.	2.3	71
102	Pharmacogenetics of irinotecan toxicity. <i>Pharmacogenomics</i> , 2004, 5, 835-843.	0.6	71
103	Tamoxifen and CYP2D6: A Contradiction of Data. <i>Oncologist</i> , 2012, 17, 620-630.	1.9	71
104	Clinically relevant drug-drug interactions in oncology. <i>British Journal of Clinical Pharmacology</i> , 1998, 45, 539-544.	1.1	70
105	Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1264-1264.	3.0	70
106	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 911-920.	0.7	69
107	Cancer pharmacogenomics: current and future applications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1603, 99-111.	3.3	67
108	CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 524-528.	1.0	67

#	ARTICLE	IF	CITATIONS
109	Exploring the Distribution of Genetic Markers of Pharmacogenomics Relevance in Brazilian and Mexican Populations. PLoS ONE, 2014, 9, e112640.	1.1	67
110	Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis. Clinical Cancer Research, 2006, 12, 6094-6099.	3.2	66
111	Population Pharmacokinetic Modeling of the Association between 63396Câ†T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 2010, 54, 5242-5250.	1.4	66
112	Knowledge, attitudes and education of pharmacists regarding pharmacogenetic testing. Personalized Medicine, 2012, 9, 19-27.	0.8	66
113	Variance in the Expression of 5-Fluorouracil Pathway Genes in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2612-2619.	3.2	64
114	Pharmacogenomics: from bedside to clinical practice. Human Molecular Genetics, 2006, 15, R89-R93.	1.4	64
115	Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer. OncoTargets and Therapy, 2018, Volume 11, 6969-6980.	1.0	64
116	High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. Annals of Neurology, 1994, 36, 920-924.	2.8	63
117	Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?. Clinical Cancer Research, 2008, 14, 8-13.	3.2	63
118	SNP databases and pharmacogenetics: great start, but a long way to go. Human Mutation, 2002, 20, 174-179.	1.1	62
119	Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Medicine, 2016, 8, 117.	3.6	61
120	Eniluracil Treatment Completely Inactivates Dihydropyrimidine Dehydrogenase in Colorectal Tumors. Journal of Clinical Oncology, 1999, 17, 2439-2439.	0.8	60
121	CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Medical Genetics, 2005, 6, 19.	2.1	60
122	Cancer Pharmacogenomics: SNPs, Chips, and the Individual Patient. Cancer Investigation, 2003, 21, 630-640.	0.6	58
123	A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2011, 67, 1225-1237.	1.1	58
124	Thymidylate Synthase Genotype-Directed Neoadjuvant Chemoradiation for Patients With Rectal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 875-883.	0.8	58
125	Pyrosequencing of Clinically Relevant Polymorphisms. , 2005, 311, 097-114.		57
126	Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget, 2016, 7, 68314-68327.	0.8	56

#	ARTICLE	IF	CITATIONS
127	A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14275-14280.	3.3	55
128	Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2053-2062.	3.2	55
129	Economic Opportunities and Challenges for Pharmacogenomics. Annual Review of Pharmacology and Toxicology, 2010, 50, 423-437.	4.2	55
130	Thiopurine Methyltransferase Genotype and the Toxicity of Azathioprine in Japanese.. Internal Medicine, 1999, 38, 944-947.	0.3	54
131	Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics, 2009, 10, 161-163.	0.6	53
132	Validation of Clinical Testing for Warfarin Sensitivity. Journal of Molecular Diagnostics, 2009, 11, 216-225.	1.2	53
133	Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet, The, 2019, 394, 511-520.	6.3	53
134	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. Journal of Human Genetics, 2013, 58, 346-352.	1.1	52
135	The candidate oncogene ZNF217 is frequently amplified in colon cancer. Journal of Pathology, 2004, 204, 282-288.	2.1	51
136	Creating and evaluating genetic tests predictive of drug response. Nature Reviews Drug Discovery, 2008, 7, 568-574.	21.5	51
137	Characterizing genetic variants for clinical action. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 93-104.	0.7	50
138	CHARACTERIZATION OF NOVEL CYP2A6 POLYMORPHIC ALLELES (CYP2A6*18 AND CYP2A6*19) THAT AFFECT ENZYMATIC ACTIVITY. Drug Metabolism and Disposition, 2005, 33, 1202-1210.	1.7	49
139	Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics, 2006, 7, 61-65.	0.6	49
140	miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β -catenin/EMT signaling cascade in gastric cancer. BMC Cancer, 2017, 17, 886.	1.1	49
141	A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochemical Pharmacology, 2005, 70, 801-808.	2.0	48
142	Exome Resequencing Identifies Potential Tumor-Suppressor Genes that Predispose to Colorectal Cancer. Human Mutation, 2013, 34, 1026-1034.	1.1	48
143	Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clinical Pharmacology and Therapeutics, 1994, 56, 503-511.	2.3	47
144	Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics, 2013, 14, 1593-1603.	0.6	47

#	ARTICLE	IF	CITATIONS
145	Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. <i>International Journal of Oncology</i> , 2004, 24, 893.	1.4	46
146	Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. <i>Investigational New Drugs</i> , 2006, 24, 393-401.	1.2	46
147	Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.	3.2	46
148	CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 753-756.	5.7	45
149	Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 804, 263-267.	1.2	45
150	Irinotecan Pharmacogenetics: Is It Time to Intervene?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1356-1359.	0.8	44
151	Novel human CYP2A6 alleles confound gene deletion analysis. <i>FEBS Letters</i> , 2004, 569, 75-81.	1.3	44
152	Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. <i>Cancer Research</i> , 2006, 66, 5029-5038.	0.4	44
153	Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. <i>Pharmacogenomics</i> , 2011, 12, 1407-1415.	0.6	44
154	Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. <i>American Journal of Cardiology</i> , 2019, 124, 539-544.	0.7	44
155	Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7342-7349.	0.8	43
156	Taxane pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 979-983.	0.7	43
157	Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. <i>Pharmacogenomics</i> , 2005, 6, 873-877.	0.6	42
158	A Novel Duplication Type of CYP2A6 Gene in African-American Population. <i>Drug Metabolism and Disposition</i> , 2007, 35, 515-520.	1.7	42
159	Systems pharmacology assessment of the 5-fluorouracil pathway. <i>Pharmacogenomics</i> , 2011, 12, 341-350.	0.6	42
160	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. <i>Oncologist</i> , 2016, 21, 795-803.	1.9	42
161	Differential Expression of the AP-1 Transcription Factor Family Members in Human Colorectal Epithelial and Neuroendocrine Neoplasms. <i>American Journal of Clinical Pathology</i> , 2005, 124, 11-19.	0.4	41
162	Etoposide pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 552-553.	0.7	41

#	ARTICLE	IF	CITATIONS
163	Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. <i>European Journal of Cancer</i> , 2010, 46, 3358-3364.	1.3	41
164	Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. <i>Journal of Pathology</i> , 2011, 223, 15-27.	2.1	41
165	Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 245-254.	1.1	41
166	Pharmacogenetics and oncology treatment for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 119-127.	0.9	40
167	Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1698-1705.	3.0	40
168	<i>In vivo</i> assessment of the metabolic activity of CYP2D6 diplotypes and alleles. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1122-1130.	1.1	40
169	Evaluation of the linearity of docetaxel pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 155-159.	1.1	39
170	Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 839-845.	1.1	39
171	Platinum pathway. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 563-564.	0.7	39
172	Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. <i>Pharmacogenomics</i> , 2004, 5, 559-569.	0.6	38
173	Genetic Variation in the B-Type Natriuretic Peptide Pathway Affects BNP Levels. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 55-62.	1.3	38
174	PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis. <i>Human Mutation</i> , 2005, 25, 110-117.	1.1	37
175	Personalizing Medicine in Geriatric Oncology. <i>Journal of Clinical Oncology</i> , 2014, 32, 2581-2586.	0.8	37
176	CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. <i>Oncology Reports</i> , 2002, 9, 653-5.	1.2	37
177	Genotypes associated with myocardial infarction risk are more common in African Americans than in European Americans. <i>Journal of the American College of Cardiology</i> , 2004, 44, 165-167.	1.2	36
178	A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy. <i>Oncologist</i> , 2014, 19, 959-965.	1.9	36
179	Pharmacogenetics: ethical problems and solutions. <i>Nature Reviews Genetics</i> , 2004, 5, 676-680.	7.7	35
180	Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. <i>Pharmacogenomics</i> , 2013, 14, 205-213.	0.6	35

#	ARTICLE	IF	CITATIONS
181	Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. <i>International Journal of Molecular Medicine</i> , 2005, 16, 573-80.	1.8	35
182	Comprehensive Evaluation of Carboxylesterase-2 Expression in Normal Human Tissues Using Tissue Array Analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2002, 10, 374-380.	0.6	34
183	Use of Pyrosequencing to Detect Clinically Relevant Polymorphisms in Dihydropyrimidine Dehydrogenase. <i>Clinical Chemistry</i> , 2003, 49, 1661-1664.	1.5	34
184	The Pharmacogenetics of Antiretroviral Therapy: A Review of Studies to Date. <i>Clinical Infectious Diseases</i> , 2004, 39, 98-106.	2.9	34
185	DNA Repair Pathway Profiling and Microsatellite Instability in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5104-5111.	3.2	34
186	Connexin37 (GJA4) genotype predicts survival after an acute coronary syndrome. <i>American Heart Journal</i> , 2007, 154, 561-566.	1.2	34
187	Making pharmacogenetic testing a reality in a community pharmacy. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, e259-e265.	0.7	34
188	The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 413-417.	1.1	34
189	PromoLign: A database for upstream region analysis and SNPs. <i>Human Mutation</i> , 2004, 23, 534-539.	1.1	33
190	Using germline genotype in cancer pharmacogenetic studies. <i>Pharmacogenomics</i> , 2009, 10, 489-493.	0.6	33
191	Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 153-162.	12.5	33
192	Pharmacogenetics: more than skin deep. <i>Nature Genetics</i> , 2001, 29, 247-248.	9.4	32
193	Chemotherapy-induced tumor gene expression changes in human breast cancers. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 181-192.	0.7	32
194	A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 796-802.	0.7	32
195	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). <i>Cancer</i> , 2015, 121, 1025-1031.	2.0	32
196	Genetic Variants in <i>CPA6</i> and <i>PRPF31</i> Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1428-1440.	0.3	32
197	Identification of NR1I2 genetic variation using resequencing. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 547-554.	0.8	31
198	Pharmacogenomics in a community pharmacy: ACT now. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2011, 51, 189-193.	0.7	31

#	ARTICLE	IF	CITATIONS
199	Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. <i>Mammalian Genome</i> , 2012, 23, 322-335.	1.0	31
200	Pharmacogenomics: The Influence of Genomic Variation on Drug Response. <i>Current Topics in Medicinal Chemistry</i> , 2004, 4, 1397-1407.	1.0	31
201	Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1947-1947.	3.0	30
202	Current pharmacogenomic studies on hERG potassium channels. <i>Trends in Molecular Medicine</i> , 2013, 19, 227-238.	3.5	30
203	Genetic Variants in <i>HSD17B3</i> , <i>SMAD3</i> , and <i>IPO11</i> Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 712-721.	2.3	30
204	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. <i>Journal of Thoracic Oncology</i> , 2006, 1, 972-978.	0.5	29
205	Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3' Untranslated Region Affect the Regulation of CYP2E1 by miR-570. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1450-1457.	1.7	29
206	Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. <i>Human Pathology</i> , 2002, 33, 1114-1119.	1.1	28
207	Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. <i>European Journal of Cancer</i> , 2008, 44, 1754-1760.	1.3	28
208	Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 179-185.	1.6	28
209	Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2004, 25, 447-51.	0.5	28
210	Therapeutic drug monitoring opportunities in cancer therapy. , 1997, 74, 39-54.		27
211	A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. <i>Journal of Applied Physiology</i> , 2003, 95, 1352-1360.	1.2	27
212	Ability of whole-genome SNP arrays to capture "must have" pharmacogenomic variants. <i>Pharmacogenomics</i> , 2008, 9, 1573-1577.	0.6	27
213	Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. <i>Pharmacogenomics</i> , 2012, 13, 113-121.	0.6	27
214	Use of <i>CYP2D6</i> genotyping in practice: tamoxifen dose adjustment. <i>Pharmacogenomics</i> , 2012, 13, 691-697.	0.6	27
215	Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity. <i>Clinical Cancer Research</i> , 2013, 19, 5769-5776.	3.2	27
216	Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. <i>Pharmacogenomics</i> , 2014, 15, 137-146.	0.6	27

#	ARTICLE	IF	CITATIONS
217	Prospective CYP2C19 -Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 563-570.	2.3	27
218	Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. <i>PeerJ</i> , 2013, 1, e31.	0.9	27
219	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	1.3	27
220	Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 993-1005.	0.5	27
221	Global pharmacogenetics: giving the genome to the masses. <i>Pharmacogenomics</i> , 2006, 7, 625-631.	0.6	26
222	ABCB1 2677G>T/A Genotype and Paclitaxel Pharmacogenetics in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4127-4129.	3.2	26
223	Can pharmacogenomics improve malaria drug policy?. <i>Bulletin of the World Health Organization</i> , 2011, 89, 838-845.	1.5	26
224	Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. <i>Pharmacogenomics</i> , 2012, 13, 955-962.	0.6	26
225	Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. <i>British Journal of Clinical Pharmacology</i> , 2000, 50, 269-272.	1.1	25
226	Characterization of the Topoisomerase I Locus in Human Colorectal Cancer. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 56-60.	1.0	25
227	Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 507-513.	0.6	25
228	wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. <i>Nucleic Acids Research</i> , 2008, 36, e41.	6.5	25
229	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 622-630.	0.7	25
230	Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. <i>Journal of Human Genetics</i> , 2016, 61, 119-127.	1.1	25
231	Propranolol Suppresses the Growth of Colorectal Cancer Through Simultaneously Activating Autologous CD8 ⁺ T Cells and Inhibiting Tumor AKT/MAPK Pathway. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 606-615.	2.3	25
232	Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 625-634.	2.3	25
233	Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. <i>Pharmacogenomics</i> , 2008, 9, 1459-1466.	0.6	24
234	Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy. <i>Pharmacogenomics</i> , 2013, 14, 555-574.	0.6	24

#	ARTICLE	IF	CITATIONS
235	VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1045-1050.	1.8	24
236	The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 29-33.	0.7	24
237	Clinical Implications of Opioid Pharmacogenomics in Patients with Cancer. <i>Cancer Control</i> , 2015, 22, 426-432.	0.7	24
238	The pharmacogenomics of drug resistance to protein kinase inhibitors. <i>Drug Resistance Updates</i> , 2016, 28, 28-42.	6.5	24
239	Value of Supportive Care Pharmacogenomics in Oncology Practice. <i>Oncologist</i> , 2018, 23, 956-964.	1.9	24
240	Pharmacogenetics of catechol-O-methyltransferase: Frequency of low activity allele in a Ghanaian population. <i>Human Mutation</i> , 2000, 16, 445-446.	1.1	23
241	Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer. <i>International Journal of Cancer</i> , 2001, 94, 297-301.	2.3	23
242	Title is missing!. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2002, 10, 374-380.	2.0	23
243	Altered Expression of TFF-1 and CES-2 in Barrett's Esophagus and Associated Adenocarcinomas. <i>Neoplasia</i> , 2005, 7, 407-416.	2.3	22
244	Clopidogrel Pharmacogenetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1681-1683.	1.1	22
245	Genetic Tailoring of Pharmacotherapy in Heart Failure: Optimize the Old, While We Wait for Something New. <i>Journal of Cardiac Failure</i> , 2012, 18, 338-349.	0.7	22
246	Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. <i>Pharmacogenomics</i> , 2013, 14, 337-339.	0.6	22
247	Aromatase Gene Polymorphisms Are Associated with Survival among Patients with Cardiovascular Disease in a Sex-Specific Manner. <i>PLoS ONE</i> , 2010, 5, e15180.	1.1	22
248	Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 29, 150-154.	1.1	21
249	The Geographic Distribution of Monoamine Oxidase Haplotypes Supports a Bottleneck During the Dispersion of Modern Humans from Africa. <i>Journal of Molecular Evolution</i> , 2001, 52, 157-163.	0.8	21
250	Genome-wide association studies: powerful tools for improving drug safety and efficacy. <i>Pharmacogenomics</i> , 2009, 10, 157-159.	0.6	21
251	Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 399-401.	0.7	21
252	The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. <i>Oncology Reports</i> , 2011, 25, 1765-72.	1.2	21

#	ARTICLE	IF	CITATIONS
253	Implications of genome-wide association studies in cancer therapeutics. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 370-380.	1.1	21
254	Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology. <i>Clinical Cancer Research</i> , 2014, 20, 2530-2540.	3.2	21
255	Clinical implementation of pharmacogenetics. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 9-16.	0.3	21
256	EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. <i>Clinica Chimica Acta</i> , 2017, 471, 216-221.	0.5	21
257	Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. <i>Cancer Research</i> , 2003, 63, 6170-3.	0.4	21
258	Drug pathways: moving beyond single gene pharmacogenetics. <i>Pharmacogenomics</i> , 2004, 5, 139-141.	0.6	20
259	Polymorphism discovery in 51 chemotherapy pathway genes. <i>Human Molecular Genetics</i> , 2005, 14, 3595-3603.	1.4	20
260	Methylation of the DPYD Promoter and Dihydropyrimidine Dehydrogenase Deficiency. <i>Clinical Cancer Research</i> , 2006, 12, 3864-3864.	3.2	20
261	UGT1A and Irinotecan Toxicity: Keeping It in the Family. <i>Journal of Clinical Oncology</i> , 2009, 27, 2419-2421.	0.8	20
262	Colorectal Cancer Cell Lines Lack the Molecular Heterogeneity of Clinical Colorectal Tumors. <i>Clinical Colorectal Cancer</i> , 2010, 9, 40-47.	1.0	20
263	Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 65-74.	1.5	20
264	Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. <i>Oncology Reports</i> , 2002, 9, 231-4.	1.2	20
265	Pharmacogenetics: using DNA to optimize drug therapy. <i>American Family Physician</i> , 2007, 76, 1179-82.	0.1	20
266	The Cancer and Leukemia Group B Pharmacology and Experimental Therapeutics Committee: A Historical Perspective. <i>Clinical Cancer Research</i> , 2006, 12, 3612s-3616s.	3.2	19
267	Applying the genome to national drug formulary policy in the developing world. <i>Pharmacogenomics</i> , 2010, 11, 633-636.	0.6	19
268	Pharmacogenomic assessment of Mexican and Peruvian populations. <i>Pharmacogenomics</i> , 2015, 16, 441-448.	0.6	19
269	β-blockers inhibit the viability of breast cancer cells by regulating the ERK/COX-2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms. <i>Oncology Reports</i> , 2019, 41, 341-350.	1.2	19
270	Vascular endothelial growth factor pathway. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 346-349.	0.7	18

#	ARTICLE	IF	CITATIONS
271	A PPAR α Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes. PLoS ONE, 2010, 5, e12584.	1.1	18
272	Pharmacogenetics and rational drug use around the world. Pharmacogenomics, 2011, 12, 897-905.	0.6	18
273	Gastric cancer pharmacogenetics: progress or old tripe?. Pharmacogenomics, 2013, 14, 1053-1064.	0.6	18
274	Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?. Current Oncology Reports, 2013, 15, 276-285.	1.8	18
275	Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups. Pharmacogenomics, 2015, 16, 817-824.	0.6	18
276	Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. Journal of Investigative Dermatology, 2017, 137, 2021-2023.	0.3	18
277	Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms. , 2003, 85, 225-238.		17
278	Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Seminars in Oncology, 2005, 32, 113-119.	0.8	17
279	CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics, 2005, 6, 59-63.	0.6	17
280	A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report. Journal of Thoracic Oncology, 2006, 1, 972-978.	0.5	17
281	Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Mining, 2012, 5, 21.	2.2	17
282	Association of Eleven Common, Low-Penetrance Colorectal Cancer Susceptibility Genetic Variants at Six Risk Loci with Clinical Outcome. PLoS ONE, 2012, 7, e41954.	1.1	17
283	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. International Journal of Oncology, 2002, 21, 1119.	1.4	16
284	CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology Reports, 2002, 9, 653.	1.2	16
285	Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients. Investigational New Drugs, 2004, 22, 285-289.	1.2	16
286	Pharmacogenetics goes 3D. Nature Genetics, 2005, 37, 794-795.	9.4	16
287	Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends in Pharmacological Sciences, 2006, 27, 498-502.	4.0	16
288	Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity. Drug Metabolism Reviews, 2008, 40, 303-315.	1.5	16

#	ARTICLE	IF	CITATIONS
289	Interaction between <i>PPARA</i> genotype and β -blocker treatment influences clinical outcomes following acute coronary syndromes. <i>Pharmacogenomics</i> , 2008, 9, 1403-1417.	0.6	16
290	Role of Pharmacogenetics as Predictive Biomarkers of Response and/or Toxicity in the Treatment of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2009, 8, 15-21.	1.0	16
291	Detection of the G>C SNP and rare mutations in the 28-bp repeat of <i>TYMS</i> using gel-based capillary electrophoresis. <i>Pharmacogenomics</i> , 2010, 11, 1751-1756.	0.6	16
292	Pharmacogenomic Contribution to Drug Response. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 80-88.	1.0	16
293	Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 135-143.	1.1	16
294	Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 68, 7-13.	0.8	16
295	Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. <i>Supportive Care in Cancer</i> , 2018, 26, 2911-2918.	1.0	16
296	Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients. <i>Oncotarget</i> , 2018, 9, 12164-12173.	0.8	16
297	Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy. <i>Oncology Reports</i> , 0, , .	1.2	16
298	Individualized cancer therapy: molecular approaches to the prediction of tumor response. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 113-119.	1.1	15
299	Challenges of implementing pharmacogenetics in the critical care environment. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 88-93.	21.5	15
300	Relationship between Red Blood Cell Thiopurine Methyltransferase Activity and Myelotoxicity in Dogs Receiving Azathioprine. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 339-345.	0.6	15
301	New Developments in the Epidemiology of Cancer Prognosis: Traditional and Molecular Predictors of Treatment Response and Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2042-2046.	1.1	15
302	Will We Ever Be Ready for Blood Level-Guided Therapy?. <i>Journal of Clinical Oncology</i> , 2008, 26, 2078-2079.	0.8	15
303	A Health Services Research Agenda for Cellular, Molecular and Genomic Technologies in Cancer Care. <i>Public Health Genomics</i> , 2009, 12, 233-244.	0.6	15
304	Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 390-394.	2.3	15
305	Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 940-948.	2.3	15
306	Ethnic differences in catechol O-methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 195-200.	5.7	14

#	ARTICLE	IF	CITATIONS
307	Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends in Pharmacological Sciences, 2003, 24, 55-58.	4.0	14
308	A comparison of association methods for cytotoxicity mapping in pharmacogenomics. Frontiers in Genetics, 2011, 2, 86.	1.1	14
309	Identification and Replication of Loci Involved in Camptothecin-Induced Cytotoxicity Using CEPH Pedigrees. PLoS ONE, 2011, 6, e17561.	1.1	14
310	Cancer pharmacogenomics, adoption by oncologists and patient benefit. Personalized Medicine, 2014, 11, 143-153.	0.8	14
311	Budget impact analysis of <i>CYP2C19</i> -guided voriconazole prophylaxis in AML. Journal of Antimicrobial Chemotherapy, 2015, 70, 3124-3126.	1.3	14
312	The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference. Pharmacogenomics, 2016, 17, 74-9.	0.6	14
313	Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenetics and Genomics, 2017, 27, 402-409.	0.7	14
314	Sink or Collaborate: How the Immersive Model Has Helped Address Typical Adolescent and Young Adult Barriers at a Single Institution and Kept the Adolescent and Young Adult Program Afloat. Journal of Adolescent and Young Adult Oncology, 2017, 6, 503-511.	0.7	14
315	The pharmacogenetics of medications used in general anesthesia. Pharmacogenomics, 2018, 19, 285-298.	0.6	14
316	Identification of a Genomic Region between <i>SLC29A1</i> and <i>HSP90AB1</i> Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clinical Cancer Research, 2018, 24, 4734-4744.	3.2	14
317	Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node metastasis. Oncology Reports, 0, , .	1.2	14
318	Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. International Journal of Oncology, 2002, 21, 1119-24.	1.4	14
319	Pharmacogenomics of cancer chemotherapy-induced toxicity. The Journal of Supportive Oncology, 2007, 5, 9-14.	2.3	14
320	A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. Journal of Thoracic Oncology, 2006, 1, 972-8.	0.5	14
321	Primum non nocere: adverse drug events must be taken seriously. Pharmacogenomics, 2007, 8, 311-314.	0.6	13
322	Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenetics and Genomics, 2009, 19, 833-842.	0.7	13
323	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS ONE, 2018, 13, e0202272.	1.1	13
324	Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study. Chemotherapy, 2019, 64, 197-204.	0.8	13

#	ARTICLE	IF	CITATIONS
325	Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2021, 27, 267-275.	3.2	13
326	Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse. <i>Pharmacology</i> , 1998, 56, 276-280.	0.9	12
327	Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 843-854.	1.9	12
328	Race does not explain genetic heterogeneity in pharmacogenomic pathways. <i>Pharmacogenomics</i> , 2008, 9, 1639-1645.	0.6	12
329	Pharmacogenetics of breast cancer therapies. <i>Breast</i> , 2009, 18, S59-S63.	0.9	12
330	Novel tagging SNP rs1495741 and 2-SNPs (rs1041983 and rs1801280) yield a high prediction of the NAT2 genotype in HapMap samples. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 322-324.	0.7	12
331	Clinically relevant cancer biomarkers and pharmacogenetic assays. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 65-72.	0.5	12
332	Analysis of uracil DNA glycosylase in human colorectal cancer. <i>International Journal of Oncology</i> , 2001, 18, 393-9.	1.4	11
333	Genetic Strategies to Individualize Supportive Care. <i>Journal of Clinical Oncology</i> , 2002, 20, 2765-2767.	0.8	11
334	Application of Pharmacogenomics in the Individualization of Chemotherapy for Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2004, 4, S43-S47.	1.0	11
335	Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics. <i>Seminars in Colon and Rectal Surgery</i> , 2008, 19, 226-230.	0.2	11
336	Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. <i>Pharmacogenomics</i> , 2009, 10, 1139-1146.	0.6	11
337	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. <i>Oncologist</i> , 2009, 14, 970-978.	1.9	11
338	Epigenetic perspectives on cancer chemotherapy response. <i>Pharmacogenomics</i> , 2014, 15, 699-715.	0.6	11
339	Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib. <i>Oncologist</i> , 2017, 22, 208-212.	1.9	11
340	Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. <i>JAMA Dermatology</i> , 2017, 153, 607.	2.0	11
341	A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 738-745.	2.3	11
342	Effect of Physician-Pharmacist Participation in the Management of Ambulatory Cancer Pain Through a Digital Health Platform: Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e24555.	1.8	11

#	ARTICLE	IF	CITATIONS
343	Modeling the cost of immune checkpoint inhibitor-related toxicities.. Journal of Clinical Oncology, 2016, 34, 6627-6627.	0.8	11
344	Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia. Annals of Saudi Medicine, 2004, 24, 21-26.	0.5	11
345	Common and rare genetic markers of lipid variation in subjects with type 2 diabetes from the ACCORD clinical trial. PeerJ, 2017, 5, e3187.	0.9	11
346	Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemotherapy and Pharmacology, 2000, 45, 423-427.	1.1	10
347	Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy. Pharmacogenomics, 2002, 3, 781-790.	0.6	10
348	Pharmacogenetics of alkylator-associated acute myeloid leukemia. Pharmacogenomics, 2006, 7, 719-729.	0.6	10
349	Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines. Molecular Cancer Therapeutics, 2011, 10, 1839-1845.	1.9	10
350	Genetic variation determines VEGF-A plasma levels in cancer patients. Scientific Reports, 2018, 8, 16332.	1.6	10
351	Genomic Medicine Year in Review: 2019. American Journal of Human Genetics, 2019, 105, 1072-1075.	2.6	10
352	Clinical Cohort Analysis of Germline <i>EGFR</i> T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precision Oncology, 2020, 4, 170-175.	1.5	10
353	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. Diabetes Care, 2021, 44, 1410-1418.	4.3	10
354	Clinical Use of Propranolol Reduces Biomarkers of Proliferation in Gastric Cancer. Frontiers in Oncology, 2021, 11, 628613.	1.3	10
355	Frequency of compound genotypes associated with β -blocker efficacy in congestive heart failure. Pharmacogenomics, 2004, 5, 553-558.	0.6	9
356	Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?. European Journal of Cancer, 2004, 40, 1807-1809.	1.3	9
357	Analysis of variation in mouse TPMT genotype, expression and activity. Pharmacogenetics and Genomics, 2004, 14, 247-254.	5.7	9
358	Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. Pharmacogenomics, 2007, 8, 519-519.	0.6	9
359	Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history. Pharmacogenomics, 2009, 10, 1413-1422.	0.6	9
360	Genomics: Applications in mechanism elucidation. Advanced Drug Delivery Reviews, 2009, 61, 369-374.	6.6	9

#	ARTICLE	IF	CITATIONS
361	Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory Guidance. <i>Annals of Internal Medicine</i> , 2011, 154, 842.	2.0	9
362	A comparison of DMET Plus microarray and genome-wide technologies by assessing population substructure. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 147-153.	0.7	9
363	The relationship between miR-302b and EphA2 and their clinical significance in gastric cancer. <i>Journal of Cancer</i> , 2018, 9, 3109-3116.	1.2	9
364	Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 103-104.	0.8	9
365	Relationship between red blood cell thiopurine methyltransferase activity and myelotoxicity in dogs receiving azathioprine. <i>Journal of Veterinary Internal Medicine</i> , 2004, 18, 339-45.	0.6	9
366	Stability of Cyclosporine in Dextrose 5%, NaCl 0.9%, Dextrose/Amino Acid Solution, and Lipid Emulsion. <i>Annals of Pharmacotherapy</i> , 1992, 26, 172-175.	0.9	8
367	Pharmacogenetics and Pediatric Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 314-323.	1.0	8
368	Assessing the utility of whole genome amplified DNA as a template for DMET Plus array. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1329-34.	1.4	8
369	Precision Medicine to Improve the Risk and Benefit of Cancer Care. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 803.	3.8	8
370	Evaluating the role of admixture in cancer therapy via <i>in vitro</i> drug response and multivariate genome-wide associations. <i>Pharmacogenomics</i> , 2015, 16, 1451-1463.	0.6	8
371	Geographic variation in molecular subtype for gastric adenocarcinoma. <i>Gut</i> , 2019, 68, 1340-1341.	6.1	8
372	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. <i>British Journal of Cancer</i> , 2022, 126, 265-274.	2.9	8
373	McLeod et al. reply. <i>Trends in Pharmacological Sciences</i> , 1996, 17, 107.	4.0	7
374	Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection?. <i>Journal of Clinical Oncology</i> , 2006, 24, 4051-4053.	0.8	7
375	MAGED2: A novel p53-dissociator. <i>International Journal of Oncology</i> , 2007, 31, 1205.	1.4	7
376	The Pharmacogenetics of Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1617-1618.	1.2	7
377	Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers. <i>Xenobiotica</i> , 2016, 46, 896-900.	0.5	7
378	Molecular predictors of prognosis and response to therapy in colorectal cancer. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 791-801.	0.5	7

#	ARTICLE	IF	CITATIONS
379	Use of pharmacogenetics to guide warfarin therapy. <i>Drugs of Today</i> , 2004, 40, 247.	2.4	7
380	Genomewide Analysis of Inherited Variation Associated with Phosphorylation of PI3K/AKT/mTOR Signaling Proteins. <i>PLoS ONE</i> , 2011, 6, e24873.	1.1	7
381	The need to shift pharmacogenetic research from candidate gene to genome-wide association studies. <i>Pharmacogenomics</i> , 2021, 22, 1143-1150.	0.6	7
382	DNA methylotype analysis in colorectal cancer. <i>Oncology Reports</i> , 2008, 20, 921-7.	1.2	7
383	Using genetic variation to optimize cancer chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2003, 1, 107-11.	0.3	7
384	Pharmacogenetic Analysis of Clinically Relevant Genetic Polymorphisms. <i>Clinical Infectious Diseases</i> , 2005, 41, S449-S452.	2.9	6
385	Pharmacokinetics after Endovascular Lung Perfusion with Cisplatin. <i>Journal of Vascular and Interventional Radiology</i> , 2006, 17, 883-888.	0.2	6
386	Differentially expressed genes in human peripheral blood as potential markers for statin response. <i>Journal of Molecular Medicine</i> , 2012, 90, 201-211.	1.7	6
387	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. <i>PLoS ONE</i> , 2014, 9, e107424.	1.1	6
388	Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv188.	3.0	6
389	American Society of Clinical Oncology Value Framework: Importance of Accurate Toxicity Data. <i>Journal of Clinical Oncology</i> , 2017, 35, 1133-1134.	0.8	6
390	Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. <i>Pharmacotherapy</i> , 2017, 37, 1043-1051.	1.2	6
391	The Future of Radiation Oncology in Soft Tissue Sarcoma. <i>Cancer Control</i> , 2018, 25, 107327481881550.	0.7	6
392	High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs. <i>PLoS Genetics</i> , 2021, 17, e1009732.	1.5	6
393	Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups. <i>GeneScreen</i> , 2001, 1, 139-142.	0.7	5
394	COMMENT ON "A FRAMESHIFT MUTATION AND ALTERNATE SPLICING IN HUMAN BRAIN GENERATE A FUNCTIONAL FORM OF THE PSEUDOGENE CYTOCHROME P4502D7 THAT DEMETHYLATES CODEINE TO MORPHINE": Drug Metabolism and Disposition, 2005, 33, 1564-1565.	1.7	5
395	Systems pharmacogenomics in yeast. <i>Pharmacogenomics</i> , 2006, 7, 255-259.	0.6	5
396	Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1064.1-1064.	1.0	5

#	ARTICLE	IF	CITATIONS
397	Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Research Notes, 2014, 7, 360.	0.6	5
398	Synergistic Chemotherapy Drug Response Is a Genetic Trait in Lymphoblastoid Cell Lines. Frontiers in Genetics, 2019, 10, 829.	1.1	5
399	Evaluating variability in fluorouracil (FU) exposure in obese and non-obese patients with colorectal cancer using full weight-based dosing.. Journal of Clinical Oncology, 2013, 31, 409-409.	0.8	5
400	Analytics of the clinical implementation of pharmacogenomics testing in 12Â758 individuals. Clinical and Translational Medicine, 2021, 11, e586.	1.7	5
401	Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure?. Oncology Research and Treatment, 2004, 27, 531-533.	0.8	4
402	Caution with ð1-adrenergic receptor genotyping*1. Clinical Pharmacology and Therapeutics, 2004, 76, 185-186.	2.3	4
403	Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans. Journal of Cardiac Failure, 2004, 10, S59.	0.7	4
404	Î2-Adrenergic Receptor Genotype Predicts Survival. Journal of Cardiovascular Nursing, 2006, 21, 474-477.	0.6	4
405	Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. Therapy: Open Access in Clinical Medicine, 2006, 3, 765-771.	0.2	4
406	Pharmacokinetics for the prescriber. Medicine, 2008, 36, 350-354.	0.2	4
407	RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncology Reports, 2011, 25, 1321-7.	1.2	4
408	Pharmacokinetics for the prescriber. Medicine, 2016, 44, 407-411.	0.2	4
409	Prospect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the way. Pharmacogenomics, 2017, 18, 1299-1304.	0.6	4
410	Clinical and pharmacogenetics associated with recovery time from general anesthesia. Pharmacogenomics, 2018, 19, 1111-1123.	0.6	4
411	Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes and Control, 2019, 30, 757-765.	0.8	4
412	An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenetics and Genomics, 2019, 29, 123-131.	0.7	4
413	Î2-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer. Cell and Bioscience, 2021, 11, 174.	2.1	4
414	Germline Variation in Colorectal Risk Loci Does Not Influence Treatment Effect or Survival in Metastatic Colorectal Cancer. PLoS ONE, 2014, 9, e94727.	1.1	4

#	ARTICLE	IF	CITATIONS
415	Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model. <i>Oncology Reports</i> , 2004, 11, 237-43.	1.2	4
416	Stability of etoposide solution for oral use. <i>American Journal of Health-System Pharmacy</i> , 1992, 49, 2784-2785.	0.5	3
417	Pharmacokinetics for the Prescriber. <i>Medicine</i> , 2003, 31, 11-15.	0.2	3
418	A mouse model for developing treatment for secondary liver tumors. <i>International Journal of Oncology</i> , 2005, 27, 113.	1.4	3
419	Fast and frugal trees: translating population-based pharmacogenomics to medication prioritization. <i>Personalized Medicine</i> , 2015, 12, 117-128.	0.8	3
420	Pharmacogenetics and Pharmacogenomics. , 2017, , 89-107.		3
421	High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 751-759.	0.6	3
422	Ethnic differences in thiopurine methyltransferase pharmacogenetics. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 773-776.	0.7	3
423	The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 633-633.	0.8	3
424	Î²-Adrenergic Receptor Inhibitor and Oncolytic Herpesvirus Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects on Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 735278.	1.6	3
425	Individualizing cancer chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2006, 4, 259-61.	0.3	3
426	Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. <i>Biomarkers in Medicine</i> , 2019, 13, 987-990.	0.6	2
427	Clarity Also Needed for Direct-to-Consumer Pharmacogenetic Tests. <i>Journal of Clinical Oncology</i> , 2020, 38, 283-284.	0.8	2
428	Pharmacokinetics for the prescriber. <i>Medicine</i> , 2020, 48, 433-438.	0.2	2
429	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	0.7	2
430	METABOLISM OF AZATHIOPRINE. <i>Transplantation</i> , 1996, 61, 1425.	0.5	2
431	Application of pharmacokinetic (PK)-guided 5-fluorouracil (FU) in clinical practice.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2595-2595.	0.8	2
432	Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?. <i>Journal of Clinical Oncology</i> , 2014, 32, 561-561.	0.8	2

#	ARTICLE	IF	CITATIONS
433	Potential germline relevance of tumor testing and the need for genetic referral.. Journal of Clinical Oncology, 2015, 33, e12552-e12552.	0.8	2
434	ARID1a as a marker of prognosis and increased sensitivity to CDK4/6, mTOR 1/2 and Src homology region 2 phosphatase (SHP 1/2) inhibitors in breast cancer (BC).. Journal of Clinical Oncology, 2019, 37, 1082-1082.	0.8	2
435	Economic benefits of adaptive abiraterone therapy for advanced prostate cancer.. Journal of Clinical Oncology, 2019, 37, e18343-e18343.	0.8	2
436	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association, 2010, 121, 21-32; discussion 32-3.	0.9	2
437	Concordance of phenotype and genotype for CYP2D6. Clinical Pharmacology and Therapeutics, 1994, 56, 463-463.	2.3	1
438	5-Fluorouracil Metabolizing Enzymes. , 1999, 28, 111-120.		1
439	Ethnicity and Pharmacogenomics. , 0, , 489-514.		1
440	Methotrexate and long-term treatment of rheumatic disease: Comment on the article by Kremer. Arthritis and Rheumatism, 2005, 52, 670-671.	6.7	1
441	Small inhibitory RNA “a tool for credentialing candidate genes. Pharmacogenomics, 2005, 6, 281-292.	0.6	1
442	Pharmacokinetics: what you need to know. Foundation Years, 2006, 2, 228-232.	0.0	1
443	Using patient DNA to optimize therapy in heart failure patients: a move toward perfection. Heart Failure Reviews, 2010, 15, 183-185.	1.7	1
444	Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care. Pharmacogenomics, 2010, 11, 13-21.	0.6	1
445	Heritage-Specific Mechanisms for Cancer Adverse Reactions: One Gene Does Not Explain the World. Journal of Clinical Oncology, 2015, 33, 1230-1231.	0.8	1
446	Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology. JAMA Neurology, 2018, 75, 793.	4.5	1
447	Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy. JCO Precision Oncology, 2018, 2, 1-18.	1.5	1
448	Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy. JCO Precision Oncology, 2019, 3, 1-7.	1.5	1
449	Abstract LB-246: Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations. , 2015, , .		1
450	Investigating the utilization of pharmacokinetic-guided fluorouracil in colorectal cancer.. Journal of Clinical Oncology, 2012, 30, e13109-e13109.	0.8	1

#	ARTICLE	IF	CITATIONS
451	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.. Journal of Clinical Oncology, 2015, 33, 3599-3599.	0.8	1
452	Tumor exome sequencing and copy number alterations reveal potential predictors of intrinsic resistance to multi-targeted tyrosine kinase inhibitors. Oncotarget, 2017, 8, 115114-115127.	0.8	1
453	Endovascular lung perfusion using high-dose cisplatin: Uptake and DNA adduct formation in an animal model. Oncology Reports, 0, , .	1.2	1
454	Hematological Pharmacogenetics. , 2006, , 111-128.		1
455	Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity. , 2015, , .		1
456	The pan-cancer, pan-biomarker landscape for precision immuno-oncology.. Journal of Clinical Oncology, 2017, 35, 43-43.	0.8	1
457	The influence of Neanderthal alleles on cytotoxic response. PeerJ, 2018, 6, e5691.	0.9	1
458	Ex-Vivo Modeling for Heritability Assessment and Genetic Mapping in Pharmacogenomics. Proceedings, 2011, 2011, 306-318.	0.3	1
459	Candidate gene selection in pharmacogenomics: biology leads the way. Pharmacogenomics, 2004, 5, 1019-1022.	0.6	0
460	Compound genotypes associated with beta-blocker efficacy in congestive heart failure are common. Journal of Cardiac Failure, 2004, 10, S57.	0.7	0
461	IMPROVING THE EFFICACY AND SAFETY OF ANTICANCER AGENTS â€” THE ROLE OF PHARMACOGENETICS. , 2006, , 285-298.		0
462	D3-02: Updated Paclitaxel-Carboplatin Pharmacogenomic (PG) Analysis of Japan-SWOG Common Arm Study in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, S397.	0.5	0
463	Pharmacokinetics for the prescriber. Medicine, 2012, 40, 357-361.	0.2	0
464	Pharmacogenetics and Pharmacogenomics. , 2013, , 362-371.		0
465	Pharmacogenomics: Success and Challenges. , 2019, , 595-606.		0
466	Cell-Based Models to Identify Genetic Variants Contributing to Anticancer Drug Response. , 2008, , 19-31.		0
467	The Predictive Value of FCGR3A Polymorphism on Clinical Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Chemotherapy. Blood, 2011, 118, 89-89.	0.6	0
468	KRAS mutation as a prognostic factor in patients undergoing hepatic resection for metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 444-444.	0.8	0

#	ARTICLE	IF	CITATIONS
469	Interrogation of polymorphisms in drug metabolism or transport genes and peripheral neuropathy during paclitaxel treatment.. Journal of Clinical Oncology, 2012, 30, 10515-10515.	0.8	0
470	Prognostic Markers in Colon Cancer. , 2013, , 131-162.		0
471	Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials.. Journal of Clinical Oncology, 2013, 31, 6501-6501.	0.8	0
472	A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance).. Journal of Clinical Oncology, 2013, 31, 11053-11053.	0.8	0
473	Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms. Cancer Drug Discovery and Development, 2014, , 255-272.	0.2	0
474	Final results of the UGT1A1-based dose modification of irinotecan and its impact on rates of severe neutropenia and hospitalization.. Journal of Clinical Oncology, 2014, 32, 461-461.	0.8	0
475	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).. Journal of Clinical Oncology, 2014, 32, e16061-e16061.	0.8	0
476	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).. Journal of Clinical Oncology, 2014, 32, 9612-9612.	0.8	0
477	Abstract 3841: Bevacizumab (BEV) and risk of arterial (ATE) and venous thromboembolism (VTE) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE). , 2014, , .		0
478	Budget impact analysis of <i>CYP2C19</i> genotyping to guide voriconazole prophylaxis in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2015, 33, e17777-e17777.	0.8	0
479	The landscape for genetic eligibility to basket clinical trials.. Journal of Clinical Oncology, 2015, 33, 1530-1530.	0.8	0
480	Breast cancer mutation frequency between smokers and non-smokers.. Journal of Clinical Oncology, 2016, 34, e13015-e13015.	0.8	0
481	Incidence and risk factors for ibrutinib associated atrial fibrillation.. Journal of Clinical Oncology, 2016, 34, e19028-e19028.	0.8	0
482	Assessment of a clinical and genetic algorithm to predict endoxifen concentration.. Journal of Clinical Oncology, 2016, 34, e12021-e12021.	0.8	0
483	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503.. Journal of Clinical Oncology, 2016, 34, 538-538.	0.8	0
484	Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance). , 2016, , .		0
485	Abstract 1409: Is it what's on the inside that counts? Melanoma mutation profiling and outcomes with immunotherapy. , 2016, , .		0
486	Abstract 2992: Propranolol induces G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
487	Abstract 1487: Gene expression and linkage analysis implicates CBLB as a mediator of rituximab resistance. <i>Cancer Research</i> , 2016, 76, 1487-1487.	0.4	0
488	Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly. <i>Blood</i> , 2016, 128, 295-295.	0.6	0
489	Incidence and average cost per toxicity in patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, 93-93.	0.8	0
490	Pan-cancer opportunities for off-label immunotherapy based on nonsynonymous mutation burden.. <i>Journal of Clinical Oncology</i> , 2017, 35, 14-14.	0.8	0
491	Comparison of incidence and average cost per toxicity in patients treated with nivolumab and pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18292-e18292.	0.8	0
492	Abstract 4567: Immunoclassification of gastric cancer in the context of clinical outcome. , 2017, , .		0
493	Abstract 1186: Propranolol could overcome BRAF inhibitors resistance by multiple mechanisms in melanoma. , 2017, , .		0
494	Level of burden of supportive care-relevant pharmacogenetic markers in general population.. <i>Journal of Clinical Oncology</i> , 2017, 35, 221-221.	0.8	0
495	CYP2C19-guided voriconazole prophylaxis in neutropenic AML patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6594-6594.	0.8	0
496	Abstract 3226: Facilitating personalized medicine with cloud-based storage and analytics. , 2020, , .		0
497	Natriuretic peptide receptor 3 genotype modulates the relationship between B-type natriuretic peptide and left ventricular end-diastolic pressure. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 765-771.	0.2	0
498	Race and smoking status associated with paclitaxel drug response in patient-derived lymphoblastoid cell lines. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 48-52.	0.7	0